Justin Smith
Stock Analyst at Bernstein
(4.31)
# 1,271
Out of 4,334 analysts
161
Total ratings
67.3%
Success rate
11.1%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QW0 argenx SE | Maintained: Buy | $915 → $877 | $697.71 | +25.70% | 11 | May 12, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | $175 | $289.00 | -39.45% | 2 | May 6, 2026 | |
| LON: GSK GSK plc | Maintained: Buy | $28 → $26 | $1,915.00 | -98.63% | 21 | May 5, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | $205 → $186 | $13,916.00 | -98.66% | 30 | May 4, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | $125 | $119.46 | +4.64% | 1 | Apr 29, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | $110 → $107 | $77.46 | +38.14% | 2 | Apr 28, 2026 | |
| SWX: ROP Roche Holding AG | Rated: Buy | $395 | $334.50 | +18.09% | 24 | Apr 27, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $152.01 | - | 1 | Mar 19, 2026 | |
| ETR: MRK Merck KGaA | Initiated Coverage: Hold | $112 | $130.00 | -13.85% | 1 | Mar 18, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Sell | $1,015 → $1,400 | $1,723.63 | -18.78% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $26.88 | - | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $25.90 | - | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $2.9 | $1.48 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $22 | $9.70 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $59.46 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $122.41 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $965 → $544 | $492.80 | n/a | 8 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $46 → $71 | $37.64 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $69 → $70 | $38.44 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $53.34 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $215.70 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $51.38 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.37 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $21.64 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,065.00 | n/a | 1 | Apr 7, 2016 |
argenx SE
May 12, 2026
Maintained: Buy
Price Target: $915 → $877
Current: $697.71
Upside: +25.70%
Novo Nordisk A/S
May 6, 2026
Maintained: Sell
Price Target: $175
Current: $289.00
Upside: -39.45%
GSK plc
May 5, 2026
Maintained: Buy
Price Target: $28 → $26
Current: $1,915.00
Upside: -98.63%
AstraZeneca PLC
May 4, 2026
Maintained: Buy
Price Target: $205 → $186
Current: $13,916.00
Upside: -98.66%
Novartis AG
Apr 29, 2026
Rated: Hold
Price Target: $125
Current: $119.46
Upside: +4.64%
Sanofi
Apr 28, 2026
Maintained: Buy
Price Target: $110 → $107
Current: $77.46
Upside: +38.14%
Roche Holding AG
Apr 27, 2026
Rated: Buy
Price Target: $395
Current: $334.50
Upside: +18.09%
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $152.01
Upside: -
Merck KGaA
Mar 18, 2026
Initiated Coverage: Hold
Price Target: $112
Current: $130.00
Upside: -13.85%
Genmab A/S
Feb 23, 2026
Maintained: Sell
Price Target: $1,015 → $1,400
Current: $1,723.63
Upside: -18.78%
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $26.88
Upside: -
Aug 17, 2025
Maintained: Hold
Price Target: n/a
Current: $25.90
Upside: -
Mar 31, 2025
Downgraded: Hold
Price Target: $11 → $2.9
Current: $1.48
Upside: n/a
Dec 10, 2024
Maintained: Buy
Price Target: $22 → $22
Current: $9.70
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $59.46
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $122.41
Upside: n/a
Dec 13, 2023
Maintained: Buy
Price Target: $965 → $544
Current: $492.80
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: $46 → $71
Current: $37.64
Upside: n/a
Nov 17, 2023
Maintained: Buy
Price Target: $69 → $70
Current: $38.44
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $53.34
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $215.70
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $51.38
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: n/a
Current: $11.37
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $21.64
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,065.00
Upside: n/a